Suicidal ideation and suicide risk psychedelic and ketamine research trials
If you are thinking about suicide or are in crisis, please get help now. Call your local emergency number, or a crisis line: in the US call or text 988, in the UK and Ireland call Samaritans on 116 123, in Israel call ERAN on 1201. For other countries, search for findahelpline.com.
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
75 registered studies are counted for suicidal ideation and suicide risk. By compound: 5 psilocybin, 2 DMT, 1 5-MeO-DMT, 68 ketamine and 1 ibogaine. By registry status: 13 recruiting, 5 not yet recruiting, 3 enrolling by invitation, 6 active, not recruiting, 25 completed, 5 terminated, 1 suspended, 6 withdrawn and 11 status not reported. By phase: 4 early phase 1, 6 phase 1, 26 phase 2, 13 phase 3, 12 phase 4, 10 not applicable and 4 not reported. Reported start years run from 2010 (earliest) to 2026 (latest).
Studies are matched when the title names suicidal ideation, suicidality, suicide or suicide risk. Non-suicidal self-injury is not matched. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 75 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 5 |
| DMT | 2 |
| 5-MeO-DMT | 1 |
| Ketamine | 68 |
| Ibogaine | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 13 | 17% |
| Not yet recruiting | 5 | 7% |
| Enrolling by invitation | 3 | 4% |
| Active, not recruiting | 6 | 8% |
| Completed | 25 | 33% |
| Terminated | 5 | 7% |
| Suspended | 1 | 1% |
| Withdrawn | 6 | 8% |
| Status not reported | 11 | 15% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 4 | 5% |
| Phase 1 | 6 | 8% |
| Phase 2 | 26 | 35% |
| Phase 3 | 13 | 17% |
| Phase 4 | 12 | 16% |
| Not applicable | 10 | 13% |
| Not reported | 4 | 5% |
Countries
Country is taken from the study's linked research site. 0 of 75 records have no country on file. The top 8 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 56 | 75% |
| Canada | 8 | 11% |
| Brazil | 3 | 4% |
| France | 3 | 4% |
| China | 2 | 3% |
| Egypt | 1 | 1% |
| Israel | 1 | 1% |
| Taiwan | 1 | 1% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 23 |
| 2020 to 2023 | 23 |
| 2015 to 2019 | 20 |
| 2010 to 2014 | 9 |
Study design
- 71 interventional and 4 observational studies.
- Median planned or actual enrolment is 53 participants (range 4 to 1,500, across 69 records that report it).
Registered studies
The 50 studies with the latest start dates, newest first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder | NCT07833761 | Not yet recruiting | Phase 1 | 2026-12-01 | Psilocybin |
| Alleviating Suicidality by Combining Psychotherapy and IM Ketamine for Rapid Treatment in the Emergency Department | NCT07868913 | Recruiting | Phase 2 | 2026-09-30 | Ketamine |
| Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress | NCT07810023 | Enrolling by invitation | Not applicable | 2026-09-10 | Ketamine |
| Assessing of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | NCT07745569 | Not yet recruiting | Phase 2 | 2026-08-31 | Psilocybin |
| Inhaled DMT for Major Depressive Disorder | NCT07562191 | Recruiting | Phase 2 | 2026-08-01 | DMT |
| Biomarker Discovery for Suicide Precision Circuit Therapeutics | NCT07723066 | Not yet recruiting | Not reported | 2026-07-01 | Ketamine |
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | NCT07569198 | Recruiting | Phase 2 | 2026-06-01 | Ketamine |
| Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies | NCT07484906 | Withdrawn | Phase 2 | 2026-05-01 | Psilocybin |
| Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts | NCT07139106 | Not yet recruiting | Phase 4 | 2026-02-01 | Ketamine |
| Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation | NCT07396220 | Enrolling by invitation | Not applicable | 2026-01-09 | Ketamine |
| Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities | NCT07120477 | Recruiting | Phase 4 | 2026-01-01 | Ketamine |
| Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality | NCT06706232 | Recruiting | Phase 2 | 2025-07-07 | Psilocybin |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior | NCT07193901 | Completed | Phase 2 | 2025-05-27 | Ketamine |
| Evaluation of the Efficacy and Safety of Subcutaneous Ketamine in the Treatment of Depressive Episode With Suicidal Ideation and/or Behavior in Adolescents | NCT06957704 | Not yet recruiting | Phase 3 | 2025-05-01 | Ketamine |
| Understanding and Treating Suicidal Ideation With Ketamine | NCT06891300 | Recruiting | Phase 2 | 2025-04-08 | Ketamine |
| Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome | NCT06698848 | Active, not recruiting | Phase 1 | 2025-01-01 | Ketamine |
| Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia | NCT07199179 | Active, not recruiting | Not reported | 2024-11-24 | Ketamine |
| Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression | NCT06511908 | Recruiting | Phase 2 | 2024-11-06 | Ketamine |
| Ketamine for OUD and Suicidal Ideation in the ED | NCT06111339 | Terminated | Phase 2 | 2024-06-14 | Ketamine |
| Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department | NCT06085937 | Recruiting | Phase 1 | 2024-05-01 | Ketamine |
| Esketamine vs ECT for Acute Suicidality | NCT06355180 | Completed | Not applicable | 2024-04-16 | Ketamine |
| Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation | NCT06366334 | Status not reported | Not applicable | 2024-01-15 | Ketamine |
| i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial | NCT06480500 | Active, not recruiting | Phase 2 | 2024-01-02 | Ketamine |
| Sustained Ketamine Effectiveness for Suicidal Ideation | NCT06806475 | Completed | Not reported | 2023-12-01 | Ketamine |
| Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan | NCT06034821 | Enrolling by invitation | Phase 4 | 2023-10-01 | Ketamine |
| Study of IV Ketamine for Emergency Department Treatment of Adolescent Suicidal Ideation | NCT05468840 | Status not reported | Phase 3 | 2023-06-01 | Ketamine |
| The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects | NCT05786066 | Recruiting | Phase 2 | 2023-04-03 | Ketamine |
| Ketamine & Crisis Response Plan for Suicidal Ideation in the ED | NCT05696691 | Recruiting | Phase 2 | 2023-01-06 | Ketamine |
| Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | NCT05450432 | Recruiting | Phase 4 | 2022-10-13 | Ketamine |
| Ketamine Versus Midazolam for Recurrence of Suicidality in Adolescents | NCT04592809 | Completed | Phase 3 | 2022-10-03 | Ketamine |
| Trifecta Research Study | NCT07717866 | Active, not recruiting | Not reported | 2022-08-01 | DMT, 5-MeO-DMT, Ibogaine |
| Ketamine Treatment of Youth Suicide Attempters | NCT04763343 | Recruiting | Phase 3 | 2022-06-27 | Ketamine |
| Ketamine Infusion for Rapid Reduction of Suicidality in Pediatrics | NCT04955470 | Terminated | Phase 1 | 2022-06-01 | Ketamine |
| Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression | NCT05177146 | Completed | Not applicable | 2022-05-04 | Ketamine |
| The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation | NCT05220410 | Completed | Phase 2 | 2022-03-28 | Psilocybin |
| Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department | NCT05217706 | Status not reported | Early Phase 1 | 2022-03-01 | Ketamine |
| Intramuscular Ketamine for Suicidal Ideation | NCT05105061 | Withdrawn | Phase 2 | 2022-02-01 | Ketamine |
| Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine | NCT04613453 | Terminated | Phase 2 | 2022-01-21 | Ketamine |
| A Single Ketamine Infusion Combined With Music for Suicidal Ideation | NCT04658420 | Status not reported | Phase 2 | 2021-07-01 | Ketamine |
| Ketamine + Cognitive Training for Suicidality in the Medical Setting | NCT04578938 | Active, not recruiting | Phase 4 | 2021-03-15 | Ketamine |
| Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention | NCT04760652 | Completed | Not applicable | 2021-03-05 | Ketamine |
| IM Ketamine vs Midazolam for Suicidal ER Patients | NCT04640636 | Suspended | Phase 4 | 2021-02-09 | Ketamine |
| A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide | NCT04669665 | Completed | Phase 2 | 2020-12-17 | Ketamine |
| Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality | NCT04101474 | Completed | Not applicable | 2020-09-01 | Ketamine |
| Opiate Suicide Study in Patients With Major Depression | NCT04116528 | Active, not recruiting | Phase 3 | 2020-08-01 | Ketamine |
| Intranasal Ketamine for Suicidal Ideation in Veterans | NCT03788694 | Withdrawn | Early Phase 1 | 2020-01-01 | Ketamine |
| Ketamine + Cognitive Training for Suicidality in the Medical Setting: Pilot | NCT04154150 | Terminated | Phase 4 | 2019-12-19 | Ketamine |
| Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department | NCT04266288 | Completed | Phase 4 | 2019-10-18 | Ketamine |
| Ketamine for Mood Disorders With Suicidal Ideation | NCT04099771 | Status not reported | Early Phase 1 | 2019-07-01 | Ketamine |
| NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression | NCT03396601 | Status not reported | Phase 3 | 2019-06-25 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | DMT | 5-MeO-DMT | Ketamine | Ibogaine
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Alcohol use disorder | Opioid use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Chronic pain